How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective

M. Shinfuku, Hiroyuki Uchida, C. Tsutsumi, T. Suzuki, K. Watanabe, Y. Kimura, Y. Tsutsumi, K. Ishii, Y. Imasaka, Masaru Mimura, S. Kapur

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: While patients with schizophrenia are often treated with psychotropic polypharmacy, how and when polypharmacy begins is not well documented. Methods: A systematic chart review of 300 patients, 100 of whom were psychotropic-free prior to their first visit, was conducted to examine 2-year longitudinal prescription patterns of concomitant psychotropics, in addition to a primary antipsychotic. Results: Overall polypharmacy occurred in 79% patients, with 2-year rates of the use of hypnotics, benzodiazepine derivative anxiolytics, anticholinergic drugs, antidepressants, and mood stabilizers were 56.7, 49.7, 38.3, 21.3, and 14.0%, respectively. Once polypharmacy had started, it was continued until their final visit in >70% of the patients. In a subgroup of 100 psychotropic-free patients, mood stabilizers, antidepressants, anticholinergic antiparkinsonian drugs, anxiolytics, and hypnotics were initiated after 2.3, 2.3, 2.1, 1.6, and 1.5 antipsychotics had been prescribed, respectively (mean duration before the introduction of a concomitant drug in days: 17.7, 121.6, 86.4, 32.1, and, 57.7, respectively). Conclusion: Routine practice deviates significantly from algorithms - with polypharmacy often being initiated early, often a without trial of other options, and once started commonly stays.

Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalPharmacopsychiatry
Volume45
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Polypharmacy
Schizophrenia
Anti-Anxiety Agents
Cholinergic Antagonists
Hypnotics and Sedatives
Antidepressive Agents
Antipsychotic Agents
Antiparkinson Agents
Benzodiazepines
Pharmaceutical Preparations
Prescriptions

Keywords

  • concomitant drugs
  • polypharmacy
  • psychotropics
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Shinfuku, M., Uchida, H., Tsutsumi, C., Suzuki, T., Watanabe, K., Kimura, Y., ... Kapur, S. (2012). How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective. Pharmacopsychiatry, 45(4), 133-137. https://doi.org/10.1055/s-0031-1297934

How psychotropic polypharmacy in schizophrenia begins : A longitudinal perspective. / Shinfuku, M.; Uchida, Hiroyuki; Tsutsumi, C.; Suzuki, T.; Watanabe, K.; Kimura, Y.; Tsutsumi, Y.; Ishii, K.; Imasaka, Y.; Mimura, Masaru; Kapur, S.

In: Pharmacopsychiatry, Vol. 45, No. 4, 2012, p. 133-137.

Research output: Contribution to journalArticle

Shinfuku, M, Uchida, H, Tsutsumi, C, Suzuki, T, Watanabe, K, Kimura, Y, Tsutsumi, Y, Ishii, K, Imasaka, Y, Mimura, M & Kapur, S 2012, 'How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective', Pharmacopsychiatry, vol. 45, no. 4, pp. 133-137. https://doi.org/10.1055/s-0031-1297934
Shinfuku, M. ; Uchida, Hiroyuki ; Tsutsumi, C. ; Suzuki, T. ; Watanabe, K. ; Kimura, Y. ; Tsutsumi, Y. ; Ishii, K. ; Imasaka, Y. ; Mimura, Masaru ; Kapur, S. / How psychotropic polypharmacy in schizophrenia begins : A longitudinal perspective. In: Pharmacopsychiatry. 2012 ; Vol. 45, No. 4. pp. 133-137.
@article{443bba197c4e4d7098207e8dd666f89c,
title = "How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective",
abstract = "Introduction: While patients with schizophrenia are often treated with psychotropic polypharmacy, how and when polypharmacy begins is not well documented. Methods: A systematic chart review of 300 patients, 100 of whom were psychotropic-free prior to their first visit, was conducted to examine 2-year longitudinal prescription patterns of concomitant psychotropics, in addition to a primary antipsychotic. Results: Overall polypharmacy occurred in 79{\%} patients, with 2-year rates of the use of hypnotics, benzodiazepine derivative anxiolytics, anticholinergic drugs, antidepressants, and mood stabilizers were 56.7, 49.7, 38.3, 21.3, and 14.0{\%}, respectively. Once polypharmacy had started, it was continued until their final visit in >70{\%} of the patients. In a subgroup of 100 psychotropic-free patients, mood stabilizers, antidepressants, anticholinergic antiparkinsonian drugs, anxiolytics, and hypnotics were initiated after 2.3, 2.3, 2.1, 1.6, and 1.5 antipsychotics had been prescribed, respectively (mean duration before the introduction of a concomitant drug in days: 17.7, 121.6, 86.4, 32.1, and, 57.7, respectively). Conclusion: Routine practice deviates significantly from algorithms - with polypharmacy often being initiated early, often a without trial of other options, and once started commonly stays.",
keywords = "concomitant drugs, polypharmacy, psychotropics, schizophrenia",
author = "M. Shinfuku and Hiroyuki Uchida and C. Tsutsumi and T. Suzuki and K. Watanabe and Y. Kimura and Y. Tsutsumi and K. Ishii and Y. Imasaka and Masaru Mimura and S. Kapur",
year = "2012",
doi = "10.1055/s-0031-1297934",
language = "English",
volume = "45",
pages = "133--137",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - How psychotropic polypharmacy in schizophrenia begins

T2 - A longitudinal perspective

AU - Shinfuku, M.

AU - Uchida, Hiroyuki

AU - Tsutsumi, C.

AU - Suzuki, T.

AU - Watanabe, K.

AU - Kimura, Y.

AU - Tsutsumi, Y.

AU - Ishii, K.

AU - Imasaka, Y.

AU - Mimura, Masaru

AU - Kapur, S.

PY - 2012

Y1 - 2012

N2 - Introduction: While patients with schizophrenia are often treated with psychotropic polypharmacy, how and when polypharmacy begins is not well documented. Methods: A systematic chart review of 300 patients, 100 of whom were psychotropic-free prior to their first visit, was conducted to examine 2-year longitudinal prescription patterns of concomitant psychotropics, in addition to a primary antipsychotic. Results: Overall polypharmacy occurred in 79% patients, with 2-year rates of the use of hypnotics, benzodiazepine derivative anxiolytics, anticholinergic drugs, antidepressants, and mood stabilizers were 56.7, 49.7, 38.3, 21.3, and 14.0%, respectively. Once polypharmacy had started, it was continued until their final visit in >70% of the patients. In a subgroup of 100 psychotropic-free patients, mood stabilizers, antidepressants, anticholinergic antiparkinsonian drugs, anxiolytics, and hypnotics were initiated after 2.3, 2.3, 2.1, 1.6, and 1.5 antipsychotics had been prescribed, respectively (mean duration before the introduction of a concomitant drug in days: 17.7, 121.6, 86.4, 32.1, and, 57.7, respectively). Conclusion: Routine practice deviates significantly from algorithms - with polypharmacy often being initiated early, often a without trial of other options, and once started commonly stays.

AB - Introduction: While patients with schizophrenia are often treated with psychotropic polypharmacy, how and when polypharmacy begins is not well documented. Methods: A systematic chart review of 300 patients, 100 of whom were psychotropic-free prior to their first visit, was conducted to examine 2-year longitudinal prescription patterns of concomitant psychotropics, in addition to a primary antipsychotic. Results: Overall polypharmacy occurred in 79% patients, with 2-year rates of the use of hypnotics, benzodiazepine derivative anxiolytics, anticholinergic drugs, antidepressants, and mood stabilizers were 56.7, 49.7, 38.3, 21.3, and 14.0%, respectively. Once polypharmacy had started, it was continued until their final visit in >70% of the patients. In a subgroup of 100 psychotropic-free patients, mood stabilizers, antidepressants, anticholinergic antiparkinsonian drugs, anxiolytics, and hypnotics were initiated after 2.3, 2.3, 2.1, 1.6, and 1.5 antipsychotics had been prescribed, respectively (mean duration before the introduction of a concomitant drug in days: 17.7, 121.6, 86.4, 32.1, and, 57.7, respectively). Conclusion: Routine practice deviates significantly from algorithms - with polypharmacy often being initiated early, often a without trial of other options, and once started commonly stays.

KW - concomitant drugs

KW - polypharmacy

KW - psychotropics

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84862567283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862567283&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1297934

DO - 10.1055/s-0031-1297934

M3 - Article

C2 - 22174025

AN - SCOPUS:84862567283

VL - 45

SP - 133

EP - 137

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 4

ER -